Effectiveness of positive allosteric modulators of metabotropic glutamate receptor 2/3 (mGluR2/3) in animal models of schizophrenia
Open Access
- 14 January 2025
- journal article
- review article
- Published by Springer Nature in Translational Psychiatry
- Vol. 15 (1) , 1-14
Abstract
Schizophrenia (SZ) is a deleterious brain disorder characterised by its heterogeneity and complex symptomatology consisting of positive, negative and cognitive deficits. Current antipsychotic drugs ameliorate the positive symptomatology, but are inefficient in treating the negative symptomatology and cognitive deficits. The neurodevelopmental glutamate hypothesis of SZ has opened new avenues in the development of drugs targeting the glutamatergic system. One of these new therapies involves the positive allosteric modulators (PAMs) of metabotropic glutamate receptors, mainly types 2/3 (mGluR2/3). mGluR2/3 PAMs are selective for the receptor, present high tolerability and can modulate the activity of the receptor for long periods. There is not much research in clinical trials regarding mGluR2/3 PAMs. However, several lines of evidence from animal models have indicated the efficiency of mGluR2/3 PAMs. In this review, focusing on in vivo animal studies, we will specifically discuss the utilization of SZ animal models and the various methods employed to assess animal behaviour before summarising the evidence obtained to date in the field of mGluR2/3 PAMs. By doing so, we aim to deepen our understanding of the underlying mechanisms and the potential efficiency of mGluR2/3 PAMs in treating SZ. Overall, mGluR2/3 PAMs have demonstrated efficiency in attenuating SZ-like behavioural and molecular deficits in animal models and could be useful for the early management of the disorder or to treat specific subsets of patients.Keywords
This publication has 131 references indexed in Scilit:
- The odour span task: A novel paradigm for assessing working memory in miceNeuropharmacology, 2007
- Altered NMDA receptor expression and behavior following postnatal hypoxia: potential relevance to schizophreniaJournal of Neural Transmission, 2006
- Biphenyl-indanone A, a Positive Allosteric Modulator of the Metabotropic Glutamate Receptor Subtype 2, Has Antipsychotic- and Anxiolytic-Like Effects in MiceThe Journal of Pharmacology and Experimental Therapeutics, 2006
- Improved Bioavailability of the mGlu2/3 Receptor Agonist LY354740 Using a Prodrug Strategy: In Vivo Pharmacology of LY544344The Journal of Pharmacology and Experimental Therapeutics, 2006
- Impairment in perceptual attentional set-shifting following PCP administration: a rodent model of set-shifting deficits in schizophreniaPsychopharmacology, 2005
- The tail suspension test as a model for assessing antidepressant activity: Review of pharmacological and genetic studies in miceNeuroscience & Biobehavioral Reviews, 2005
- Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugsMolecular Psychiatry, 2004
- Dopaminergic dysfunction in alcoholism and schizophrenia – psychopathological and behavioral correlatesEuropean Psychiatry, 2002
- Potentiation of DOM-induced stimulus control by non-competitive NMDA antagonistsLife Sciences, 2000
- Anxiety, defence and the elevated plus-mazeNeuroscience & Biobehavioral Reviews, 1997